Summary Purpose: To establish the long-term efficacy and tolerability of vagus nerve stimulation (VNS) in children with a Lennox-like syndrome. Method: This study was a longitudinal observational prospective cohort analysis. Baseline: 6 months. Follow-up: 24 months. Screening (baseline and every 6 months): MRI (baseline only), EEG, neuropsychological evaluation, ECG and blood sampling for antiepileptic drug levels. Nineteen children are included. Results: A seizure frequency reduction of 20.6% was found at the end of the follow-up period. No relationship was detected between the length of the stimulation period and the reduction in the seizure frequency. 21% of the patients showed a reduction in seizure frequency of 50% or more. The seizure severity showed improvement in the first 12 months of treatment. The largest seizure reduction was found in the patients with highest frequency of background activity at the baseline EEG. Neuropsychological findings: no negative impact on behaviour, moderate improvement in function, behaviour and mood. Largest seizure reduction was found in the group with the highest baseline mental function. The scores for mental age improved independently of the seizure control. Twelve patients (63%) experienced minor side effects, which subsided after 1 month. Conclusion: (1) There was a significant reduction in seizure frequency and severity. (2) No serious side effects were recorded. (3) No negative effects on cognition or quality of life were apparent. (4) Patients with highest baseline mental functioning showed the highest seizure reduction. (5) Those patients with less disturbed EEG (high background activity and less interictal epileptic activity) showed the highest seizure reduction.
Introduction
Epilepsy has a prevalence of 0.7-0.8%. Adequate seizure control is achieved in only 75-80% of these patients while 20-25% suffer from intractable epilepsy. 1 Vagal nerve stimulation (VNS) might be an alternative treatment option as randomised studies show a success rate of 12% in intractable epilepsy. The success rate is defined as the measured treatment response rate corrected for placebo, measuring bias and natural course, while the response rate is defined as a seizure frequency reduction of 50% or more. This success rate is small but it is in line with the success rates of new antiepileptic drugs in pharmacotherapy resistant patients, which range from 12 to 29%. 2 
Clinical trials in children
The effectiveness of VNS is positively correlated to the duration of treatment, both in adults and children. 3, [4] [5] [6] [7] [8] Hornig studied the effect of VNS in 19 children, 6 of them being diagnosed as having Lennox-Gastaut syndrome. 5 The preoperative baseline period was 1 month and the postoperative follow-up 21-29 months. He reported that five of the six children showed a seizure frequency reduction of 90% or more.
Parker presented the results of VNS in 16 children with encephalopathic epilepsy. 8 Ten of these children were diagnosed as Lennox-Gastaut syndrome, four suffered from myoclonic epilepsy and two from myoclonic astatic epilepsy. The situation 1 year after surgery was compared with a 2-month preoperative baseline period. There was one drop out. Two children showed an increase in seizure frequency of more than 50% and four a decrease of more than 50%. The mean reduction was 17%. A similar study was conducted by Lundgren et al. 6 In this case, 16 children aged between 4 and 19 years were evaluated during a baseline period of 6 months and the results were compared with those from a treatment period of 12-24 months. Eight children suffered from partial seizures and eight from generalised seizures; four of these were diagnosed as LennoxGastaut syndrome. Six children (37%) showed a reduction in seizure frequency of 50% or more; one of them was diagnosed as Lennox-Gastaut syndrome.
Ben Menachem reported the results of a prospective long-term open study with a follow-up of 3-64 months. 4 The last 3 months of treatment with VNS were compared with a preoperative baseline of 3 months. The subgroup of patients with LennoxGastaut syndrome showed a mean reduction in seizure frequency of 24%.
Nagarajan et al. studied the efficacy of VNS in children with refractory epilepsy. 9 The children showed multiple seizure characteristics and the majority suffered from a moderate to severe mental handicap. 62.5% achieved a seizure frequency reduction of 50% or more; 25% of this prognostically unfavourable group achieved a seizure reduction of more than 90%. Similar results were found by Zamponi et al. in a group of 13 children with intractable epilepsy, multiple seizure characteristics, mixed aetiology, and moderate to severe mental handicap: 10 66% of the children showed a seizure frequency reduction of 50% or more.
In these studies the reported side effects were minor and most patients showed habituation. It should be stressed that the reason for discontinuing VNS was primarily due to insufficient clinical results and rarely due to side effects or complications of treatment. 2, 3, [11] [12] [13] [14] In 1998, the Epilepsy Centre Kempenhaeghe and the Neurosurgical Department of the University Hospital Maastricht initiated a prospective study in children with refractory epilepsy, diagnosed as Lennox-Gastaut syndrome or Lennox-like types of epilepsy.
The issues to be studied were the efficacy and tolerability of VNS in children with a LennoxGastaut syndrome or Lennox-like type of epilepsy in long-term follow-up.
Methods

VNS surgery and VNS stimulator
Bipolar stimulation of the vagus nerve was undertaken by placing the electrodes around the left vagus nerve, while the pulse generator (Neurocybernetic prothesis NCP ® , Cyberonics Inc., Webster, TX, USA) is normally implanted below the clavicle. 15 Because the group of children involved in this study were mentally retarded and may show behavioural problems, we chose to implant the device below the pectoralis major to prevent them manipulating the device and to give a more acceptable cosmetic effect. All surgical procedures were performed by the same neurosurgeon in the Maastricht University Hospital (M.W.B.). The device was programmed telemetrically the day after the implantation (H.J.M.M.) using the following parameters: stimulation for 30 s followed by a stimulation-free period of 3 min, pulse width 500 s, output current 0.25 mA. Over a period of 10-20 days, the output current was increased by 0.25 mA per day. Should the patient experience side effects, such as coughing or a tingling sensation in the throat, the stepwise increase of the output current was delayed for 1 or 2 days. Finally, all children were stimulated with an output current of 1.5-2 mA.
Should the effects of VNS not meet the expectations of the parents after 3 months of treatment, the stimulation parameters were changed. As a result, 11 patients changed to so-called 'rapid cycling' (cycles of 7-s stimulation with a stimulation-free interval of 18 s) during the subsequent 3-month period.
Stimulation can be switched off by placing a handheld magnet over the generator. In children who were prone to aspirate, the device was switched off during their mealtimes.
Patient population
Nineteen children with malignant childhood epilepsy resembling the Lennox-Gastaut syndrome were included in this study. This clinical syndrome is characterised by a large number of seizures and therapy resistance. 16, 17 Inclusion criteria were: 
Study design
The present study is a prospective longitudinal observational cohort analysis. The patients served as their own controls. The baseline characteristics were determined over an initial 6-month period. After implantation and activation of the stimulator, the patients were followed for 24 months. During the first 12 months, where ever possible, no antiepileptic drug changes were permitted.
Medical outcome measures
During the 6 months prior to the implantation of the device, data were collected from each patient to serve as a baseline. Follow-up measurements were undertaken at 6, 12, 18 and 24 months post-operatively. In this way, each patient served as his or her own control.
Using the ILAE Classification, 18 the seizures reported by the parents were categorised as follows:
• Tonic seizures (drop-attacks with tonic contraction of the body--the patient usually falls backwards); • Atonic seizures (drop-attacks with complete relaxation of the body--usually the patient drops onto their knees, falls sideways or forwards); • Myoclonic seizures (short-lived contractions of the face or limbs); • Tonic-clonic seizures (initial tonic contraction of the body followed by regular shaking of the limbs); • Absences (short moments of decreased consciousness with or without minor accompanying symptoms).
The tonic, atonic, myoclonic and tonic-clonic seizures were scored separately. A cluster of five or more seizures were categorised as a series. Seizures with a duration of 15 min or more, and seizures recurring within 30 min without full recovery of consciousness, were coded as status epilepticus. The absences were counted for a period of 1 h on the same day of the week and at the same time. In the week preceding the visit to the out-patient department, the seizures were scored every day, at the same time, and for a period of 1 h.
The seizure severity was scored with the adapted Chalfont Severity Scales as described by O'Donoghue. 19 All children were given at least one, and maximally three, antiepileptic drugs. Generally, this medication was not changed during the first postoperative 12 months. For two of the children the following exceptions applied: discontinuation of valproate (daily dose of 450 mg) because of loss of appetite and of lamotrigine (daily dose of 50 mg) because of behavioural problems.
Neuropsychological outcome measures
To assess the effects of VNS on behaviour in the present study, we defined two separate domains, namely, cognitive function and quality of life.
The assessment of cognitive functions aimed to establish the mental age of the child using three different tests depending on the level of functioning: the Dutch version of the Bayley Developmental Scale 20 (with scores ranging from 2 to 30 months mental age); the McCarthy Developmental Scale 21 (with score ranging from 2(1/2) to 8(1/2) years mental age) and the WISC RN 22 (with scores ranging from 6 to 17 years mental age).
Quality of life was assessed by looking at areas of functioning that are recognised in daily life, namely, independence (using the SRZ Scale 23 ), behaviour, i.e. the tendency to develop behaviour disorders (using the SGZ Scale 24 ) and the mood characteristics of the patient (using the TVZ Scale 25 ). All scales use proxy-scores (parents' reports or, in the case of in-patients, the nurses' reports).
VNS was continues during testing. When convulsive seizures occurred, the testing procedure was postponed until the next day. When absence seizures occurred, testing was stopped until the parents (usually present during the testing session) ascertained an optimal level of functioning.
Results
The study group consisted of 15 males and 4 females at baseline, which reflects the predominance of the male gender in patients suffering from epilepsy ( Table 1 ). The average age was 10.8 years, ranging from 5.9 to 18.8 years. Most patients (16/19) were treated on an out-patient basis, only 3 patients were hospitalised. In 13 of the patients, the diagnosis of Lennox-Gastaut syndrome was confirmed. Six patients had 'Lennox-like' syndromes: three had Doose syndrome, one myoclonic absence epilepsy, and two Dravet syndrome. The aetiology was known in seven children (perinatal anoxia in four, dysplasia in two and viral meningo-encephalitis in one). Mean age of onset of the epilepsy was 2.2 years (with a range of 0-8 years) and the average duration of epilepsy was 8.1 years. All children had multiple seizure types and treatment consisted of a broad variety of antiepileptic drugs: valproate (n = 9), carbamazepine (n = 7) and lamotrigine (n = 6) were the most frequently used. Most patients were on combination therapy (n = 16), ranging from two to four antiepileptic drugs. Three patients were on monotherapy (one oxcarbazepine, one lamotrigine and one valproate).
Mean number of seizures per month
Seizure frequency
The seizure frequency decreased by 50% or more in four patients; one of these patients being seizure-free. Eight patients showed a seizure reduction of less than 50% and six patients an increase in seizure frequency. In total, 21% of the patients showed a seizure reduction of 50% or more. Fig. 1 . shows the mean number of seizures per month. Comparing baseline frequency with seizure frequency at the end of the study a reduction of 20.6% was found (Wilcoxon signed rank test, P = 0.03). A positive relationship between the duration of stimulation and seizure frequency reduction was not found. The seizure frequency for each seizure type was also evaluated (Fig. 2.) . Although some seizure types seem to reacted better to VNS than others, the differences were not significant.
The seizure severity was scored with the adapted Chalfont Seizure Severity Scale as presented by O'Donoghue. 19 The major improvements on this scale were seen in the first 12 months (Wilcoxon signed rank test, P = 0.002). 
EEG
EEG analyses at baseline showed that the frequency of background activity was highest in responders (7.4 Hz in responders versus 5.6 Hz in non-responders). The level of epileptic activity at baseline was higher in non-responders than in responders, as was the minimal and maximal heart rates ( Table 2) . However, the group of responders was very small and so the differences did not reach the level of statistical significance. Table 3 shows the comparisons between baseline and the follow-up period up to endpoint (24 months Table 2 Minimal and maximal heart rate frequency at baseline while patient is awake and during sleep.
Neuropsychological results
Mean minimal heart rate frequency (awake)
Mean maximal heart rate frequency (awake) of stimulation) for mental age and the three 'quality of life' variables. No statistically significant change over time was found for any of these comparisons. In fact, all variables showed a similar profile throughout the follow-up period. The largest and most consistent change was the increase of 4.2 months in the mental age function from baseline to endpoint. The group was subdivided according to overall response (baseline to endpoint) to VNS treatment as follows: >50% reduction in seizure frequency (responders), <50% reduction in seizure frequency, no change or increase in seizure frequency ( Table 4 ).
The three subgroups had statistically significant different levels of mental function (P = 0.04) demonstrating that the response to the VNS varies with level of mental function, the most positive effects being seen in those patients with the highest level of mental functioning (89.3 months versus 15.0 and 20.3 months for the other two groups).
Complications and side effects
No surgical complications occurred. Many patients suffered from side effects, but these effects were minor and transient. These side effects included: coughing (n = 4) and a strange feeling in the throat described as a tickling sensation (n = 2) resolved after the first week of stimulation. Hoarseness, only occurred during the time the patient was ANOVA for difference in mental age: F-value 3.873; P = 0.04; ANOVA for difference in 'change of mental age': F-value 1.810; P = 0.20.
stimulated, was present in seven patients. This side effect persisted until the second month of stimulation. One patient encountered swallowing difficulties. For this reason, the device was deactivated during meals.
Discussion
This study evaluated the long-term efficacy and tolerability of VNS in a group of children with pharmacotherapy resistant epilepsy. Our study showed an average reduction in seizure frequency of 20.6% after 24 months of treatment with VNS, which is, while relatively modest, still comparable with the results of the controlled VNS studies EO3 and EO5 (with an average reduction ranging from 24.5 to 27.9%). 26, 27 Twenty-one percent of the patients showed a reduction in seizure frequency of 50% or more; this is also compares favourably with the EO3 and EO5 studies (31 and 23.4%, respectively). This relatively modest reduction in seizure frequency might be explained, at least partially, by the specific patient group included, namely, those with a severe type of refractory epilepsy and mental retardation, multiple seizure types and a high seizure frequency. The prognosis of the children in this study group would be considered to be unfavourable for normal treatment. 16, 17 In contrast, the EO3 and EO5 studies related to a group of patients aged 13-60 years (10% of these patients were younger than 20 years) suffering from partial seizures only (6 or more per month). 28 The results are also comparable with earlier reports on VNS in similar patient groups which showed that 25% of the patients had a reduction in seizure frequency of 50% or more, with a mean value for the individual patient of about 20-30%. 4, 6, 8, 29 The results of the study by Hornig et al. 5 are exceptional in that five of six patients with LennoxGastaut syndrome showed a reduction in seizure frequency of 90% or more. However, in that study the baseline period of 1 month might have been too short to be representative of the natural course of the epilepsy in which case the patients could have been recruited during a temporary exacerbation of their epilepsy and to have returned to their mean seizure frequency during treatment with VNS. The same good results were found by Nagarajan et al. 9 In this study, the children had multiple seizure characteristics and the majority had a moderate to severe mental handicap yet 25% of this prognostically unfavourable group achieved a seizure reduction of more than 90%. Again a baseline period of 1 month was used. The results in terms of more than 50% seizure frequency reduction were nevertheless reproduced by Zamponi et al. 10 in which of the 13 children with intractable epilepsy, multiple seizure characteristics, mixed aetiology and moderate to severe mental handicap in all, 66% of the children experienced a seizure reduction of 50% or more. In this case, a baseline period of 3 months was used.
George et al. 3 reported that the effects of VNS are positively correlated to the length of the treatment period. However, in our group of patients we could not find a relation between duration of stimulation and treatment effect. The relative seizure increase in the second year of treatment might be attributed to a temporary deterioration of five children in the 15th month.
As VNS did not influence cognitive measure and quality of life measurements unfavourably, it may be justified to conclude that VNS does not have any adverse effects on higher order functions or quality of life, even at long term (Table 3 ). This confirms the clinical anecdotal information and may be important for parents with regard to the treatment of their child. In addition, there was a mild improvement in mental age, although the change of 4.2 months is modest compared to the 24 months of follow-up. Also the results of behavioural and cognitive function at 24 months are similar to the follow-up results after 6 months of VNS. In this specific patient population efficacy of VNS apparently does not increase with the duration of treatment. 30 Our results at 6-month follow-up also revealed a positive effect of VNS on behaviour independent of seizure control. These findings are supported by those of Lundgren et al., 6 Dodrill and Morris 31 and Parker et al. 8 We suggested that this may be interpreted as a direct (positive) effect of VNS on behaviour. 32 Further follow-up showed that this effect did not persist over time and decline by the end of the study. Table 4 shows that group 3 (the group without any effects of VNS on seizure frequency) still improved in mental age even though this effect is modest (1.7 months) and smaller than that found at the 6-month follow-up (29 months) . This may be due to the specific group in our study that had severe mental handicaps thereby causing a 'ceiling' effect on the response to treatment. Thus, it may be worthwhile to test the direct effects of VNS on behaviour in a group of epileptic children who are not mentally retarded.
To date there is only limited information on the characteristics of patients who respond to VNS. Ben Menachem et al. described differences between responders and non-responders based on the findings of a long-term follow-up observational study 4. They reported that 50% of the patients with a right-sided focus (n = 16) responded whereas only 25% of those with a left-sided focus did so (n = 12). Eight patients could be classified as Lennox-Gastaut, suffering mainly from generalised tonic-clonic seizures and absences. Of these, five responded. Patients with atonic seizures did not respond but of the nine patients with primary generalised epilepsy five responded: they all suffered from absence seizures exclusively.
There is also an indication that baseline seizure frequency has its impact on the response to VNS. Thus, the higher the baseline seizure frequency, the better the responsiveness to VNS. [33] [34] [35] In the present study, the four children who responded to VNS in terms of seizure frequency reduction had the highest frequency of baseline background activity, the lowest quantity of interictal epileptic activity and highest mental level at baseline as compared to non-responders. These three factors might be interpreted as a measure of brain function. The lower the frequency of background activity and the higher the interictal activity the higher the degree of brain damage.
The absence seizures seem to respond better than other seizure types.
The best treatment effect was found in the group with highest mental age at baseline (89.3 months for responders versus 15.0/20.3 months for non-responders; P = 0.04). Mental retardation can, therefore, be characterised as a negative prognostic factor for treatment with VNS.
